Revenue
2019
2020
2020
2021
2022
2023
2024
2025
MYRIAD GENETICS INC (MYGN)
Price—Loading quote
Net income
2019
2020
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
Total cash / debt
CashTotal debt
2019
2020
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 · Dec 31 | 2020 · Jun 30 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M | $557.1M | $638.6M | $851.1M | $743.7M | $728.7M | $740.5M | $722.5M | $778.2M | $613.2M | $496.0M | $402.1M | $362.6M | $326.5M |
| Gross profit | $576.6M | $585.4M | $517.0M | $476.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $106.8M | $113.4M | $88.7M | $85.4M | $81.9M | $73.3M | $77.2M | $85.9M | $70.8M | $74.4M | $70.6M | $75.5M | $67.5M | $53.7M | $42.6M | $27.8M | $21.9M | $17.9M |
| Operating expenses | $963.8M | $708.9M | $774.4M | $617.0M | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$387.2M | −$123.5M | −$257.4M | −$140.6M | −$190.5M | −$289.7M | −$231.7M | $7.6M | $121.9M | $44.0M | $153.4M | $133.6M | $274.4M | $228.0M | $180.3M | $157.8M | $135.1M | $126.5M |
| EBITDAderived | −$333.5M | −$62.3M | −$195.5M | −$87.9M | −$127.7M | — | −$159.7M | $80.6M | $176.3M | $92.3M | $180.2M | $158.6M | $288.2M | $236.9M | $189.4M | $165.0M | $142.2M | $135.9M |
| Net income | −$365.9M | −$127.3M | −$263.3M | −$112.0M | −$27.2M | −$223.6M | −$199.5M | $4.6M | $133.3M | $17.4M | $117.2M | $79.8M | $176.2M | $147.2M | $112.2M | $100.7M | $152.3M | $84.6M |
| Basic EPSper diluted share | -$3.95 | -$1.41 | -$3.18 | -$1.39 | -$0.35 | -$2.99 | -$2.69 | $0.06 | $1.92 | $0.25 | $1.67 | $1.12 | $2.33 | $1.82 | $1.33 | $1.12 | $1.58 | $0.91 |
| Diluted EPSper diluted share | -$3.95 | -$1.41 | -$3.18 | -$1.39 | -$0.35 | -$2.99 | -$2.69 | $0.06 | $1.85 | $0.25 | $1.60 | $1.07 | $2.25 | $1.77 | $1.30 | $1.10 | $1.54 | $0.86 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 8, 2026Form 4 · 10b5-1 | Kumar RashmiDirector | SellCommon Stock | 15.0K | $4.46 | $66.9K | 171.9K |
| May 14, 2026Form 4 | Bisaro PaulDirector | BuyCommon Stock | 7.5K | $3.69 | $27.7K | 97.4K |
| Mar 9, 2026Form 4 | Raha Samraat S.President and CEO | BuyCommon Stock | 40.0K | $5.00 | $200.0K | 493.1K |
| Feb 27, 2026Form 4 | Phanstiel S. LouiseDirector | BuyCommon Stock | 48.0K | $4.66 | $223.7K | 282.0K |
| Feb 26, 2026Form 4 | Phanstiel S. LouiseDirector | BuyCommon Stock | 50.4K | $4.80 | $242.0K | 234.0K |